SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

BAFNA PHARMACEUTICALS

BSE: 532989 28 Jun 2025
Healthcare
₹ 74.01
Bafna Pharmaceuticals Limited specializes in Pharmaceuticals within the Healthcare sector.

BAFNA PHARMACEUTICALS - Share Price & Details

Market Cap
₹189.0
High /Low
96.0 / 67.8
Stock P/E
30.0
Book Value
₹35.8
Dividend Yield
0.0
ROCE
8.28
ROE
₹7.61
Face Value
10.0
PEG Ratio
0.75
EVEBITDA
₹15.4
Debt
28.2
CMP / FCF
-79.5
Debt to equity
₹0.33
NP Ann
4.15
High price all time
234.0
Piotroski score
₹5.0
Graham Number
37.6
No. Eq. Shares
2.37
Net CF
₹2.04
Net profit
4.15
Price to book value
2.23
Interest Coverage
₹3.31
Low price all time
3.55
Industry PE
32.7
Reserves
₹61.2
Free Cash Flow
₹0.34

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
BAFNA PHARMACEUTICALS LTD.NANANANA189.030.0
KREBS BIOCHEMICALS & INDUSTRIE64.39-82.6861.01-3.83189
BILCARE LTD.NANANANA17944.8

Peer Comparison Chart


About BAFNA PHARMACEUTICALS

Bafna Pharmaceuticals Limited, with Security Code 532989, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Who are in the management team of Bafna Pharma.?

(08 Jun 2025)
As of March 2022, Bafna Pharma's management team includes Shanmugam Hemalatha (Chairperson/Executive Director), Vinayak Dinesh Dendukuri...
Read more →

Summentor Pro Concludes 4th MSME & Startup Innovation Summit in Odisha Empowering Growth

(05 Jun 2025)
Bhubaneswar (Odisha) [India], June 4: Summentor Pro, India's leading business development consulting firm, proudly hosted the 4th Edition of...
Read more →

Bafna Pharmaceuticals Reports Strong Profit Growth Amid Concerns Over Non-Operating Income Reliance

(29 May 2025)
Bafna Pharmaceuticals has announced its financial results for the quarter ending March 2025, highlighting a significant increase in profitability.
Read more →

Bafna Pharma Standalone March 2025 Net Sales at Rs 39.06 crore, down 5.65% Y-o-Y

(27 May 2025)
Net Sales at Rs 39.06 crore in March 2025 down 5.65% from Rs. 41.40 crore in March 2024. Story continues below Advertisement.
Read more →

Bafna Pharmaceuticals standalone net profit declines 10.27% in the March 2025 quarter

(27 May 2025)
Sales decline 5.65% to Rs 39.06 crore. Net profit of Bafna Pharmaceuticals declined 10.27% to Rs 1.31 crore in the quarter ended March 2025 as against Rs...
Read more →

Q4 results: Aurobindo Pharma, Shilpa Medicare, Nazara Technologies to announce March quarter numbers on May 26; check details

(26 May 2025)
Auropbindo Pharma, Shilpa Medicare, Yathath Hospital, Nazara Technologies, Olectra Greentech, Orchid Pharma, RateGain Travel technologies...
Read more →